Evidence map›Paper›PMID 42953287›Full record

ReviewChemical & biomedical imaging2026

Recent Advances in Near-Infrared Probes for Monitoring Drug Treatment Responses: Toward Efficacy Evaluation and High-Throughput Screening.

Xinle Li, Shaobo Hou, Zhenghui He, Yi Sun, Yingxin Sun, Yalun Yao, Zi Long, Chong Duan, Jian-Liang Zhou

Abstract readReview
In one paragraph

Review in Chemical & biomedical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xinle LiSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Shaobo HouSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Zhenghui HeSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Yi SunSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Yingxin SunSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Yalun YaoSchool of Civil and Architectural Engineering, Jiangxi University of Water Resources and Electric Power, Nanchang 330099, China.
Zi LongSchool of Civil and Architectural Engineering, Jiangxi University of Water Resources and Electric Power, Nanchang 330099, China.
Chong DuanSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.ORCID https://orcid.org/0000-0003-1033-2415
Jian-Liang ZhouSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.ORCID https://orcid.org/0000-0002-4716-7807

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate drug efficacy evaluation and efficient potential drug screening are cornerstones of translational pharmacology, as they can directly underpin the optimization of therapeutic regimens, acceleration of drug development pipelines, and improvement of patient clinical outcomes. However, conventional analytical approaches for these tasks often suffer from inherent limitations, including invasiveness, low sensitivity to subtle molecular changes, inability to achieve real-time in vivo monitoring of therapeutic dynamics, and poor compatibility with physiologically relevant disease models. In response to these unmet needs, near-infrared (NIR) fluorescent probes have emerged as transformative tools, leveraging a suite of unique advantages, such as noninvasiveness, ultrahigh sensitivity, excellent target specificity, operational simplicity, deep tissue penetration, and cost-effectiveness, to enable precise, spatiotemporal tracking of drug actions in both preclinical and early clinical settings. This review provides a comprehensive, up-to-date overview of recent advances in the rational design and translational applications of NIR probes for drug efficacy assessment and high-throughput screening (HTS). Specifically, NIR probes can systematically detect drug-induced biochemical and microenvironmental alterations and, when are integrated into automated HTS platforms, significantly enhancing screening sensitivity, throughput, and physiological relevance. Finally, we delineate key challenges impeding the widespread clinical translation of NIR probe technology and outline future research directions. Progress in therapeutic areas holds profound potential to refine personalized drug treatment strategies, accelerate late-stage clinical trial validation, and drive paradigm-shifting innovations across the global pharmaceutical industry.

Indexed as

BiomarkersDrug efficacyHigh-throughput screeningNear-infrared probesTherapeutic monitoring

Identifiers

PMID42953287
PMCPMC13715351

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.